ERNA on Nasdaq

Ernexa Therapeutics Inc.

American pharmaceutical preparations company based in Cambridge. Summary from the record

$2.05 down 0.06 (2.87%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 19, 2026.

Overview

Compare with PMGC Holdings Inc., Yarrow Bioscience, Inc. or Trevena Inc, or pick any stock.

  • TickerERNA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersCambridge, Massachusetts1
  • Incorporated inDE3
  • Business address1035 Cambridge Street, Suite 18A, Cambridge, Ma 021413
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

“Mesenchymal Stem Cell Therapies” - Cell-based therapies based on MSCs are described.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

83.5%Gross margin5
-2693.1%Operating margin5
-7652.7%Net margin5
755.9%Revenue growth, 20245
-2618.4%Return on equity5
-$16.2MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue16¢$96.0K
  • Other costs78¢$456.0K
  • Income tax5¢$30.0K

Out of $582.0K in revenue.5 The company lost money this year.

Financial statements

Revenue6785$582.0K in 2024−97% since 2019
0$5.0M$10.0M$15.0M$20.0M2019: $19.8M$19.8M20192020: $5.8M$5.8M2020−71%2022: $0$020222023: $68.0K$68.0K20232024: $582.0K$582.0K2024+756%
Gross profit785$486.0K in 2024
-$200.0K0$200.0K$400.0K$600.0K2022: $0$020222023: -$168.0K-$168.0K20232024: $486.0K$486.0K2024
Operating income6910785-$15.7M in 2024+790% since 2019
-$150.0M-$100.0M-$50.0M02019: -$1.8M-$1.8M20192020: -$7.2M-$7.2M2020+311%2021: -$113.7M-$113.7M2021+1469%2022: -$33.2M-$33.2M2022−71%2023: -$21.1M-$21.1M2023−36%2024: -$15.7M-$15.7M2024−26%
Net income6910785-$44.5M in 2024+2076% since 2019
-$150.0M-$100.0M-$50.0M02019: -$2.0M-$2.0M20192020: -$7.3M-$7.3M2020+256%2021: -$122.5M-$122.5M2021+1581%2022: -$24.6M-$24.6M2022−80%2023: -$21.7M-$21.7M2023−12%2024: -$44.5M-$44.5M2024+106%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue$582.0K
Cost of revenues$96.0K
Gross profit$486.0K
Research and development$4.2M$4.6M
General and administrative$5.2M$13.1M
Gain on lease termination-$1.6M
Total operating expenses$9.3M$16.2M
Loss from operations-$9.3M-$15.7M
Forward sales contract expense-$5.8M
Gain (loss) on extinguishment of debt$765.0K-$22.4M
Change in fair value of convertible notes$1.0M
Change in fair value to bridge notes derivative liability-$1.5M
Change in fair value of warrant liabilities$1.0K$414.0K
Change in fair value of contingent consideration$66.0K
Interest income$83.0K$249.0K
Interest expense-$27.0K-$6.8M
Other income, net$215.0K$70.0K
Total other expense, net-$4.8M-$28.8M
Loss before income taxes-$14.1M-$44.5M
Benefit (provision) for income taxes$45.0K-$30.0K
Net loss-$14.1M-$44.5M
Series A preferred stock dividend-$16.0K-$16.0K
Net loss attributable to common stockholders-$14.1M-$44.6M
Net loss per common share - basic-$2.24-$48.96
Net loss per common share - diluted-$2.24-$48.96
Weighted average shares outstanding - basic6.3M shares910.0K shares
Weighted average shares outstanding - diluted6.3M shares910.0K shares

Compare Ernexa Therapeutics Inc. with another company

Leadership

Who has led Ernexa Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dario Loreto Santana2006–2007
  2. Terry Allan Bateman2009–2010
  3. Michael J. Bush2010–2012
  4. Allen Wolff2019–2021
  5. Howard J. Federoff2022
  6. Matthew Angel2022–2023
  7. Sanjeev Luther2024–now

President

  1. Dario Loreto Santana2006–2007
  2. Victor Tyrone Lam2007
  3. Howard J. Federoff2022
  4. Matthew Angel2022–2023
  5. Sanjeev Luther2024–now

Chief financial officer

  1. Kendra Berger2006–2012
  2. Allen Wolff2014–2019
  3. Andrew C. Jackson2022
2010201520202025
Board members and other officers (58)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJames Bristol named Dec 20, 2023 to Apr 11, 202580
  • DirectorRichard W. Wagner named Jul 26, 202381
  • DirectorNicholas J. Singer named Dec 16, 202282
  • DirectorErin S. Enright named Mar 23, 202283

Former names

  • Eterna Therapeutics Inc.Oct 24, 2022 to Apr 4, 20253
  • Brooklyn ImmunoTherapeutics, Inc.Mar 26, 2021 to Oct 14, 20223
  • NTN BUZZTIME INCSep 1, 2005 to Mar 23, 20213
  • NTN COMMUNICATIONS INCFeb 14, 1994 to Dec 20, 20053

Timeline

  1. Jan 3, 2024New chief executive Sanjeev Luther becomes CEO14
  2. Jun 1, 2022New chief executive Matthew Angel becomes CEO16
  3. Mar 15, 2022New chief executive Howard J. Federoff becomes CEO15
  4. Sep 24, 2019New chief executive Allen Wolff becomes CEO17
  5. Apr 22, 2010New chief executive Michael J. Bush becomes CEO18
  6. Feb 3, 2009New chief executive Terry Allan Bateman becomes CEO19
  7. Jul 12, 2006New chief executive Dario Loreto Santana becomes CEO20

Filings

324 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 81 major events, 80 insider forms, 39 large holders, 8 private raises, 94 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Sep 22, 20263 EDGAR
  3. Sep 16, 20268-K EDGAR
  4. Sep 16, 20268-K EDGAR
  5. Sep 1, 20264 EDGAR
  6. Sep 1, 20264 EDGAR
  7. Sep 1, 20264 EDGAR
  8. Sep 1, 20264 EDGAR
  9. Sep 1, 20264 EDGAR
  10. Sep 1, 20264 EDGAR
  11. Aug 27, 20263 EDGAR
  12. Aug 6, 202610-Q EDGAR
  13. Jul 2, 20268-K EDGAR
  14. Jul 2, 20268-K EDGAR
  15. Jun 26, 20268-K EDGAR
  16. May 20, 2026SCHEDULE 13G/A EDGAR
  17. May 15, 2026SCHEDULE 13G/A EDGAR
  18. May 15, 2026SCHEDULE 13G/A EDGAR
  19. May 14, 2026SCHEDULE 13G EDGAR
  20. May 14, 2026SCHEDULE 13G EDGAR

The 324 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 8 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 10, 2026Cherington Charles10% ownerBuy4,000,000$0.50$2.0MForm 4
Jun 9, 2025Cherington Charles10% ownerBuy21,241,163$0.10$2.1MForm 4
Apr 2, 2025Cherington Charles10% ownerBuy3,768,397$0.10$376.8KForm 4
Oct 29, 2024Cherington Charles10% ownerBuy13,252,112Form 4
Sep 24, 2024Cherington Charles10% ownerBuy13,252,112Form 4
Dec 2, 2022Cherington Charles10% ownerBuy261,756$3.28$858.6KForm 4
Dec 2, 2022Singer Nicholas JasonDirectorBuy283,286$3.28$929.2KForm 4
Dec 2, 2022HALPERN JOHN D10% ownerBuy335,920$3.28$1.1MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 31, 2025Raised $7.2 million in a private offering of equity Form D: 15 investors so far Form D
  2. Sep 24, 2024Raised $1.1 million in a private offering of equity Form D: 5 investors so far Form D
  3. Sep 24, 2024Raised $3.9 million in a private offering of debt Form D: 11 investors so far Form D
  4. Dec 15, 2023Raised $7.8 million in a private offering of securities Form D: $9.2 million offered in all Form D
  5. Jul 14, 2023Raised $8.7 million in a private offering of securities Form D: 19 investors so far Form D
  6. Jul 14, 2023Raised $8.7 million in a private offering of securities Form D: 19 investors so far Form D
  7. Dec 2, 2022Raised $7.7 million in a private offering of equity Form D: 20 investors so far Form D
  8. Mar 9, 2022Raised $12 million in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Citadel Advisors LLC15,104$100.4K0.0%New
Vanguard Fiduciary Trust Co8,336$55.4K0.0%New
Dauntless Investment Group, LLC6,000$39.9K0.1%New
Vanguard Capital Management LLC5,684$37.8K0.0%New
Tradewinds Capital Management, LLC361$2.4K0.0%New
BlackRock, Inc.33$2190.0%New
Assetmark, Inc5$330.0%New
Bnp Paribas Financial Markets1$70.0%New
SBI Securities Co., Ltd.1$70.0%New
Steward Partners Investment Advisory, LLC0$10.0%New
Activest Wealth Management0$00.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
    Yahoo FinanceERNA quote
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93